CDRO (CDRO) Stock Price & Analysis
CDRO (CDRO) rose 2.66% to USD 9.27 as of July 25, 2026 at 05:19 UTC, according to Nexqual real-time market data.
CDRO last closed at USD 9.03; the session ranged USD 9.05–9.32 on volume of 13,032 shares. Market capitalization is $421.51M, with a 52-week range of USD 5.18–10.26 (NCM). Source: Nexqual, July 25, 2026 at 05:19 UTC.
Key Statistics (as of July 25, 2026 at 05:19 UTC)
| Price | USD 9.27 |
|---|---|
| Change | ▲ 2.66% (up) |
| Previous Close | USD 9.03 |
| Open | USD 9.16 |
| Day Range | USD 9.05 – 9.32 |
| 52-Week Range | USD 5.18 – 10.26 |
| Volume | 13,032 shares |
| Market Cap | $421.51M |
| Exchange | NCM |
Technical Analysis (CDRO)
Nexqual's technical model rates CDRO "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.83 (neutral) |
| vs SMA50 | Below (USD 9.5) |
| MACD | -0.1 (negative) |
Analyst Ratings (CDRO)
Wall Street analysts rate CDRO "Buy" based on 3 analysts, with a mean price target of USD 12 (range USD 10–14), per Nexqual as of July 25, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 12 |
| High Target | USD 14 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 2 / 2 / 0 |
Earnings (CDRO)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 0.05 |
| Revenue Estimate | $58.27M |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Financials & Fundamentals (CDRO)
| Total Revenue | $210.41M |
|---|---|
| Revenue Growth (YoY) | +6.60% |
| Gross Margin | +88.12% |
| Operating Margin | +2.60% |
| Profit Margin | +0.61% |
| ROE | +4.89% |
| Debt / Equity | 13.68 |
| Current Ratio | 1.37 |
| Total Cash | $49.98M |
| Total Debt | $3.93M |
| Free Cash Flow | $14.88M |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Financial Health Score (CDRO)
Nexqual rates CDRO's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 05:19 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 88%, operating 3% |
| Balance Sheet | Strong — $50M cash vs $4M debt, net cash position |
| Cash Flow | Solid — FCF $15M, 7% margin |
| Efficiency | Weak — ROE 5%, ROA 4.6% |
Ownership (CDRO)
| Insider Ownership | +67.32% |
|---|---|
| Institutional Ownership | +11.63% |
| Shares Outstanding | 45.47M |
| Float | 14.80M |
| Short % of Float | +2.47% |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Leadership (CDRO)
CDRO is led by Aviv Sher (age 45), Chief Executive Officer, per Nexqual as of July 25, 2026 at 05:19 UTC.
| Chief Executive Officer | Aviv Sher (age 45) |
|---|---|
| Executive Vice Chairman of the Board | Moshe Edree (age 58) |
| Chief Financial Officer | Marcus Arildsson (age 52) |
| Chief Operating Officer | Deborah Guivisdalsky (age 43) |
| Director of Investor Relations | Guillermo Lancha |
Major Backers & Investors (CDRO)
Notable institutional backers of CDRO include BAMCO Inc., BARON SELECT FUNDS-Baron Emerging Markets Fund, FNY Investment Advisers, LLC, according to Nexqual as of July 25, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BAMCO Inc. | 7.7% |
| BARON SELECT FUNDS-Baron Emerging Markets Fund | 7.44% |
| FNY Investment Advisers, LLC | 1.43% |
| MMBG Investment Advisors Co. | 0.81% |
| UBS Group AG | 0.81% |
| Morgan Stanley | 0.34% |
| Exchange Traded Concepts LLC | 0.28% |
| Wealthspire Advisors, LLC | 0.11% |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals Inc | USD 0.3 | ▲ 0% |
| ADSE | ADS-TEC ENERGY PLC | USD 12.01 | ▲ 0.08% |
| BRAG | Bragg Gaming Group Inc. | USD 1.63 | ▼ 2.98% |
| BCOW | 1895 Bancorp of Wisconsin, Inc. | USD 17.7 | ▲ 0.74% |
| SABS | SAB Biotherapeutics, Inc. | USD 3.51 | ▼ 1.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:19 UTC. This page is informational and not investment advice.